Veru reported that enobosarm preserved lean mass and shifted weight loss toward fat alongside semaglutide in a Phase IIb study. We review the early data.
On September 9, 2026, Veru presented new findings at the 12th Annual Cantor Fitzgerald Global Healthcare Conference. The company detailed a clinical development approach for enobosarm as a potential muscle preservation therapy. Enobosarm is an oral selective androgen receptor modulator that Veru is developing for use alongside GLP-1 therapy. The presentation positioned the investigational drug as a potential companion to semaglutide for older adults with obesity.
One of the most common mistakes our team sees in adults over forty is focusing solely on the scale. We have watched people celebrate rapid weight reduction while their energy plummeted and their metabolism slowed. They were often losing muscle instead of just fat due to unmanaged nutrition and a lack of tracking body composition and protecting functional muscle. Shifting the conversation from generic scale numbers to physical capability has been one of the most impactful changes WeightRestart has championed.
Veru CEO Mitch Steiner outlined the objective of their clinical program during the September presentation. The stated goal was to change the composition of weight reduction from a mixture of fat and lean tissue to predominantly fat loss. Steiner emphasized that preserving muscle and physical function is a central focus for future therapeutic development. The company hopes to provide a tool that supports this specific biological goal.
When adults initiate GLP-1 medicines like semaglutide, they typically experience a significant decrease in appetite. This appetite reduction drives weight reduction but can lead to the breakdown of lean tissue if left unmanaged. A 2026 Endocrine Reviews article summarized a systematic review of 20 randomized trials involving 15,782 participants to clarify this effect. The review found that lean mass accounted for approximately 26 percent of total weight loss across these studies.
The published review evidence suggests that GLP-1 associated weight reduction can reduce absolute lean mass while improving overall body composition proportions. This happens because fat mass may decline more substantially than lean tissue over time, which changes how GLP-1 medications affect exercise, muscle, and athletic performance. The exact percentage of lean tissue lost can vary depending on the specific medication used. The Endocrine Reviews article reported agent-specific estimates of 35.2 percent for semaglutide, 25.4 percent for tirzepatide, and 26.8 percent for liraglutide.
Veru is proposing a combination strategy to address this physiological mechanism directly. Semaglutide would target appetite and weight reduction, while enobosarm would influence peripheral tissue composition. The company cited prior bimagrumab and trevogrumab research to support the hypothesis that preserving muscle is compatible with additional fat loss. However, the conference coverage did not provide complete independent trial citations or body composition tables for those older studies.
The mainstream media frequently covers new obesity medications with sensationalized language. Veru management described the weight lost in the relevant treatment comparison as representing a total shift toward fat. Readers might interpret these statements as proof that enobosarm guarantees complete muscle preservation for all GLP-1 users. However, the early Phase IIb QUALITY study results do not independently establish that the treatment works for everyone.
The 2026 Endocrine Reviews article offered a critical caution for interpreting body composition data from any trial. The review clarified that DEXA-derived lean mass is not an exact measure of skeletal muscle. A DEXA scan measures lean or fat-free compartments rather than providing a perfect measurement of muscle tissue. A higher percentage of lean mass after weight loss does not necessarily mean that a person fully retained their skeletal muscle.
The trial population for these findings is also very narrow. Veru noted that patients older than 65 with a body mass index above 35 appeared to show the strongest results in the QUALITY study. These specific findings may not apply directly to adults aged 35 to 60, younger users, or people taking a different GLP-1 medicine. The company is actively positioning the therapy for an older and more functionally vulnerable population rather than a general fitness audience.
It is crucial to remember that weight management involves a complex biological system. Weight change is influenced by appetite, nutrition, and movement. Sleep, environment, and specific medical treatments also play a massive role. Readers should treat enobosarm as an investigational strategy awaiting larger-scale evidence rather than an approved solution. Consistent resistance training and distributing daily protein intake evenly across meals remain practical parts of a muscle-conscious weight management plan.
Veru evaluated enobosarm at 3 mg and 6 mg against a placebo in its Phase IIb QUALITY study. These participants were adults with obesity who were beginning semaglutide treatment. The active weight loss portion of QUALITY lasted 16 weeks. After that initial period, semaglutide was discontinued and participants continued on enobosarm or a placebo for an additional 12 weeks.
Veru said the 3-mg enobosarm dose preserved lean mass during the 16-week weight loss period. The company reported that the weight lost in the combination group was directed toward fat rather than lean tissue. Management noted that the 6-mg dose produced more fat loss but did not provide additional lean mass preservation. Veru selected the 3-mg dose for further development based on these specific body composition observations.
The study also evaluated physical capability using a specific functional test. The stair climb test used an eight-step climb, computer timing, and an additional load equal to 10 percent of body weight. Veru reported that 44 percent of participants receiving semaglutide plus a placebo experienced a greater-than-10 percent decline in stair climb power. Adding 3-mg enobosarm reduced that incidence by up to 60 percent at the 16-week mark.
Steiner argued that the FDA is more likely to focus on patient function rather than a cosmetic lean mass claim. Veru linked stair climb decline with severe outcomes like balance problems, falls, and fractures. Management presented this rationale rather than citing new documented findings from the short QUALITY study.
The company also tracked safety signals and liver enzyme levels throughout the trial. The 3-mg group had one patient with a threefold ALT increase that resolved while treatment continued. The 6-mg group experienced more liver enzyme elevations, which influenced the final dose selection. Veru stated that no bilirubin elevations or Hy’s Law cases were observed during this study period.
The short 16-week active period of the QUALITY study leaves significant questions about long-term outcomes. To address this, the company is currently running the fully enrolled Phase IIb PLATEAU trial with 239 participants. This study is designed to run for 68 weeks and compares enobosarm plus semaglutide against semaglutide alone. PLATEAU focuses strictly on adults older than 65 with a body mass index above 35.
The medical community is awaiting the planned 32-week interim analysis of the PLATEAU trial. Veru expects to release this analysis in the first quarter of 2027. The interim look is intended to examine lean mass and fat mass measured by DEXA, but body weight is not included in that analysis. Veru described PLATEAU as a more comprehensive follow-up that adds longer-duration body composition data and quality-of-life questionnaires.
Drug developers are increasingly framing obesity treatment around the functional consequences of weight loss. However, positive Phase IIb findings would not independently establish efficacy or support regulatory approval. The company noted that a future Phase III obesity program could require approximately 4,500 participants to validate these concepts. To support this ongoing research, Veru reported approximately $24 million in cash as of June 30, 2026, with an expected runway into mid-2027.
Veru also disclosed a clinical supply agreement with Novo Nordisk that includes information sharing and access to trial data. This agreement includes a first right of negotiation for a potential licensing or collaboration opportunity involving a Novo product and enobosarm. We will continue to monitor these trials to see if functional capabilities and muscle preservation can be successfully maintained during medically assisted weight reduction.
WeightRestart shares research-led guidance on weight loss, metabolism, nutrition, strength, appetite, sleep and recovery. Our goal is to make complex health information clear, practical and useful for people building progress they can maintain.
Learn how to build a weight-management approach around better information, realistic expectations and habits you can keep using.
read the blog
